负载CCR5抗体的纳米颗粒治疗小鼠子宫内膜异位症模型的实验研究
该研究合成负载CC型趋化因子受体5抗体(anti-CCR5)的聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒,在小鼠子宫内膜异位症模型中比较其与单纯anti-CCR5对腹腔巨噬细胞比例及IL-10、TGF-β分泌的影响,并检测异位内膜细胞增殖与侵袭。结果显示PLGA/anti-CCR5可控制释放anti-CCR5,更明显降低巨噬细胞比例及IL-10、TGF-β水平,作者认为其可能通过抑制巨噬细胞分泌IL-10和TGF-β抑制异位内膜细胞增殖和侵袭。
要点
- PLGA/anti-CCR5纳米颗粒成功合成,第3~24天可持续释放anti-CCR5。
- 第7、14天PLGA/anti-CCR5组巨噬细胞比例较anti-CCR5组下降更明显(P<0.01)。
- PLGA/anti-CCR5组IL-10和TGF-β水平低于anti-CCR5组(P<0.01),且第3、7、14天逐渐减少。
核心结论
- 在小鼠子宫内膜异位症模型中,PLGA/anti-CCR5纳米颗粒可能通过抑制巨噬细胞分泌IL-10和TGF-β来抑制异位内膜细胞的增殖和侵袭。
- 作者认为PLGA/anti-CCR5纳米颗粒为子宫内膜异位症的治疗提供了新的思路。
研究设计与样本
- 实验研究:合成PLGA/anti-CCR5纳米颗粒并评估anti-CCR5累积释放。
- 建立小鼠子宫内膜异位症模型,分为对照组、anti-CCR5组和PLGA/anti-CCR5组。
- 分离培养异位内膜细胞(EEC)及腹腔液中巨噬细胞,用流式细胞术检测腹腔液巨噬细胞比例,ELISA检测IL-10和TGF-β水平,用5-溴脱氧尿苷增殖试剂盒和matrigel侵袭试剂盒检测EEC增殖与侵袭。
主要发现
- PLGA/anti-CCR5纳米颗粒成功合成,第3~24天可持续释放anti-CCR5。
- PLGA/anti-CCR5组巨噬细胞比例逐渐减少,第7天[(4.5±1.5)%]与第3天[(6.3±0.6)%]比较差异有统计学意义(P<0.01),第14天[(2.6±0.7)%]与第7天比较差异有统计学意义(P<0.05)。
- 第7、14天PLGA/anti-CCR5组巨噬细胞比例较anti-CCR5组下降更明显(P<0.01)。
- 第7、14天PLGA/anti-CCR5组IL-10和TGF-β水平低于anti-CCR5组(P<0.01),且PLGA/anti-CCR5组第3、7、14天IL-10和TGF-β水平逐渐减少(P<0.01)。
- IL-10抗体+TGF-β抗体联合作用后EEC增殖和侵袭[分别为(70.8±7.6)%、(50.2±9.1)%]较单用均降低(P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate whether poly (lactic-co-glycolic acid) (PLGA) as protein delivery vehicles that encapsulate CC chemokine receptor 5 antibody (anti-CCR5) has more suppressive function on macrophages than single anti-CCR5 in mouse endometriosis model. Methods: The PLGA/anti-CCR5 nanoparticles were synthesized. The cumulative release of anti-CCR5 from PLGA/anti-CCR5 nanoparticles was evaluated. The mouse endometriosis model was established and divided into control group, anti-CCR5 group and PLGA/anti-CCR5 group. Meanwhile, ectopic endometrial cells (EEC) and macrophages isolated from peritoneal fluid were cultured in vitro. Flow cytometry was used to detect the proportion of macrophages in the peritoneal fluid of each group. The secretion of interleukin 10 (IL-10) and transforming growth factor β (TGF-β) in each group were determined by ELISA. The proliferation and infiltration of EEC were detected by 5-bromodeoxyuridine proliferation kit and matrigel invasion kit. Results: The PLGA/anti-CCR5 nanoparticles were successfully synthesized. The mouse endometriosis model was established and the EEC and macrophages were cultured. Compared with the anti-CCR5 without nanoparticles, the bioconjugate PLGA/anti-CCR5 nanoparticles could control the release of anti-CCR5 from day 3 to day 24. The proportion of macrophages in PLGA/anti-CCR5 group were gradually reduced compared with those in anti-CCR5 group (P<0.01), the ratios of day 7 [(4.5±1.5)%] and day 3 [(6.3±0.6)%], day 14 [(2.6±0.7)%] and day 7 were significantly different (P<0.01 and P<0.05). PLGA/anti-CCR5 reduced IL-10 and TGF-β levels relative to anti-CCR5 (P<0.01),and decreased gradually on day 3, day 7, and day 14 (P<0.01). Anti-IL-10+anti-TGF-β could reduce the proliferation [(70.8±7.6)%] and invasion ability [(50.2±9.1)%] of EEC (P<0.05). Conclusions: In mouse endometriosis model, PLGA/anti-CCR5 may inhibit the proliferation and invasion of EEC by inhibiting the secretion of IL-10 and TGF-β by macrophages, suggesting that it provide a new idea for the treatment of clinical endometriosis. 目的: 聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒作为蛋白质载体用来负载CC型趋化因子受体5抗体(anti-CCR5),合成负载anti-CCR5的PLGA纳米颗粒(简称:PLGA/anti-CCR5),分析其抑制小鼠子宫内膜异位症的动物实验研究。 方法: 合成PLGA/anti-CCR5纳米颗粒,分析纳米颗粒中anti-CCR5的累积释放。建立小鼠子宫内膜异位症模型,并分为对照组、anti-CCR5组、PLGA/anti-CCR5组,同时分离、培养异位内膜细胞(EEC)及腹腔液中的巨噬细胞;流式细胞仪检测各组腹腔液中巨噬细胞的比例,ELISA方法测定各组腹腔镜中细胞因子白细胞介素10(IL-10)和转化生长因子β(TGF-β)的水平。用5-溴脱氧尿苷细胞增殖检测试剂盒和人工基底膜基质凝胶matrigel侵袭检测试剂盒检测EEC的增殖、浸润情况,同时,检测IL-10抗体和TGF-β抗体作用后EEC的增殖和侵袭情况。 结果: 成功合成了PLGA/anti-CCR5纳米颗粒,成功建立了小鼠子宫内膜异位症模型。PLGA/anti-CCR5纳米颗粒在第3~24天可持续释放anti-CCR5。PLGA/anti-CCR5组巨噬细胞比例逐渐减少,第7天[(4.5±1.5)%]与第3天[(6.3±0.6)%]、第14天[(2.6±0.7)%]与第7天分别比较,差异均有统计学意义(P<0.01、P<0.05);在第7、14天,PLGA/anti-CCR5组的巨噬细胞比例较anti-CCR5组下降更明显(P<0.01)。在第7、14天,PLGA/anti-CCR5组相比于anti-CCR5组IL-10和TGF-β的水平更低(P<0.01),且PLGA/anti-CCR5组在第3、7、14天IL-10和TGF-β的水平逐渐减少(P<0.01)。IL-10抗体+TGF-β抗体联合作用后EEC的增殖和侵袭[分别为(70.8±7.6)%、(50.2±9.1)%]相比于单用均降低(P<0.05)。 结论: 在小鼠子宫内膜异位症模型中,PLGA/anti-CCR5纳米颗粒可能通过抑制巨噬细胞分泌IL-10和TGF-β来抑制EEC的增殖和侵袭,PLGA/anti-CCR5纳米颗粒为子宫内膜异位症的治疗提供了新的思路。.
引用
- Zhang YY, Li P. [Experimental research on the treatment of mouse endometriosis model with nanoparticles loaded with CCR5-antibody]. Zhonghua Fu Chan Ke Za Zhi. 2019. PMID: 31648444. doi:10.3760/cma.j.issn.0529-567x.2019.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。